Salarius Pharmaceuticals (SLRX) - Long-Term Debt to Capital

Salarius Pharmaceuticals (SLRX) is penetrating the epigenetics niche to combat pediatric tumors, where demand is immense due to a shortage of therapies. The business relies on outsourcing all development and synthesis through external contractors, and the separate_debt_long_eq metric on GURU.Markets stands at 0.00. The linear price action on this chart illustrates the market trend for the company, whose developments are protected by patents and orphan drug status, creating a colossal financial barrier to entry.

Investors assess a business's financial stability through its degree of dependence on borrowed capital. This indicator compares the volume of loans with a maturity of over one year against the amount of equity. For the pre-commercial biotech Salarius Pharmaceuticals (SLRX), the absence of revenue makes the debt load a critical risk. High leverage coupled with linear growth in R&D expenses could lead to bankruptcy. By analyzing the trend of the long-term debt-to-equity ratio, one can determine the company's margin of safety.